Hu Peng, Zhang Li, Hu Hongtao, Wang Di, Chen Jia, Xiao Jinghuan, Wu Hang, Qi Luming, Qin Kaihua, Zuo Xiaohong, Li Juan
School of Health Preservation and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
School of Comprehensive Health Industry, Sichuan Tourism University, Chengdu, Sichuan, China.
Front Pharmacol. 2025 Aug 1;16:1608582. doi: 10.3389/fphar.2025.1608582. eCollection 2025.
As a traditional food-medicine dual-purpose substance, red yeast rice (RYR) has gained wide attention for its lipid-lowering activity. However, existing studies mainly focus on the liver-targeted effects of statin-like components, with limited systematic insights into its lipid metabolism regulation via gut microbiota. This study combines high-fat diet (HFD)-induced hyperlipidemia mouse models, 16S rRNA gene sequencing, untargeted metabolomics, and fecal microbiota transplantation (FMT) to investigate the potential of RYR extract in improving lipid metabolism through gut microbiota modulation. The results showed that RYR extract significantly improved body weight, serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) levels, and hepatic lipid deposition in HFD-fed mice. Additionally, RYR extract effectively restored the intestinal structural damage and enhanced intestinal barrier function. 16S rRNA revealed that RYR extract significantly modulated the gut microbiota, increasing the abundance of beneficial bacteria such as Bifidobacterium and restoring the ratio of Firmicutes to Bacteroidota. Metabolomics analysis revealed that RYR extract significantly modulated the gut microbiota-derived metabolites, particularly in the tryptophan metabolism and phenylalanine metabolism. FMT experiments showed that the fecal microbiota from RYR-treated group obviously improved the blood lipid levels, liver pathology, and intestinal function in HFD-fed mice. These results suggest that RYR extract improves lipid metabolism through the modulation of gut microbiota and related metabolic pathways, which provides new insights into the mechanism research of RYR's lipid-lowering effect.
作为一种传统的药食两用物质,红曲米因其降脂活性而受到广泛关注。然而,现有研究主要集中在他汀类成分的肝脏靶向作用,对其通过肠道微生物群调节脂质代谢的系统见解有限。本研究结合高脂饮食(HFD)诱导的高脂血症小鼠模型、16S rRNA基因测序、非靶向代谢组学和粪便微生物群移植(FMT),研究红曲米提取物通过调节肠道微生物群改善脂质代谢的潜力。结果表明,红曲米提取物显著改善了高脂饮食喂养小鼠的体重、血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平和肝脏脂质沉积。此外,红曲米提取物有效恢复了肠道结构损伤并增强了肠道屏障功能。16S rRNA显示,红曲米提取物显著调节肠道微生物群,增加双歧杆菌等有益菌的丰度,并恢复厚壁菌门与拟杆菌门的比例。代谢组学分析表明,红曲米提取物显著调节肠道微生物群衍生的代谢物,特别是在色氨酸代谢和苯丙氨酸代谢方面。FMT实验表明,红曲米处理组的粪便微生物群明显改善了高脂饮食喂养小鼠的血脂水平、肝脏病理和肠道功能。这些结果表明,红曲米提取物通过调节肠道微生物群和相关代谢途径改善脂质代谢,为红曲米降脂作用的机制研究提供了新的见解。